Omnicell (OMCL) EBITDA Margin (2010 - 2026)
Omnicell's (OMCL) quarterly EBITDA Margin came in at 10.39% in Q2 2026, up 760.0% year-over-year from 1.21% in Q2 2025, and up 91.09% quarter-over-quarter from 5.44% in Q1 2026.
Powered by 
Analysis
Omnicell (OMCL) EBITDA Margin (2010 - 2026) Analysis & Trends
Omnicell (OMCL) has reported EBITDA Margin for 17 consecutive years, with 10.39% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA Margin rose 760.0% year-over-year to 10.39% in Q2 2026; TTM through Jun 2026 was 4.65%, a 330.0% increase from a year earlier, with the FY2025 full-year figure at 0.44%, up 41.0% from the prior year.
- EBITDA Margin was 10.39% for Q2 2026 at Omnicell, up from 5.44% in the prior quarter.
- Over five years, EBITDA Margin peaked at 10.39% in Q2 2026 and troughed at 12.89% in Q4 2022.
- A 5-year average of 0.02% and a median of 1.96% in 2022 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin sank 1661 bps in 2022 and jumped 1307 bps in 2024, its largest moves.
- Over 5 years, EBITDA Margin stood at 12.89% in 2022, then increased by 30 bps to 9.03% in 2023, then jumped by 145 bps to 4.04% in 2024, then sank by 97 bps to 0.13% in 2025, then jumped by 7764 bps to 10.39% in 2026.
- The last three EBITDA Margin figures came in at 10.39% (Q2 2026), 5.44% (Q1 2026), and 0.13% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | 24.33% |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | 30.66% |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | 10.39% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.39% |
| Mar 31, 2026 | 5.44% |
| Dec 31, 2025 | 0.13% |
| Sep 30, 2025 | 2.65% |
| Jun 30, 2025 | 2.79% |
| Mar 31, 2025 | -4.31% |
| Dec 31, 2024 | 4.04% |
| Sep 30, 2024 | 2.32% |
| Jun 30, 2024 | 1.16% |
| Mar 31, 2024 | -8.88% |
| Dec 31, 2023 | -9.03% |
| Sep 30, 2023 | 1.24% |
| Jun 30, 2023 | 2.59% |
| Mar 31, 2023 | -7.90% |
| Dec 31, 2022 | -12.89% |
| Sep 30, 2022 | 5.31% |
| Jun 30, 2022 | 3.77% |
| Mar 31, 2022 | 1.59% |
| Dec 31, 2021 | 3.73% |
| Sep 30, 2021 | 9.92% |